References
- Jones G, Trafford DJH, Hollis BW, Makin HLJ. Vitamin D: cholecalciferol, ergocalciferol and hydroxylated metabolites. Modern Chromatographic Analysis of Vitamins. Vol. 30. 2nd ed., HJ. Nelis, WE. Lambert, AP DeLeenheer. Chromatographic Science Series, Marcel Dekker, New York 1992; 73–151
- Jones Glenville, Hogan David B, Yendt Edmund, Hanley David A. Vitamin D metabolites and analogs in the treatment of osteoporosis. Can Med Assoc 1996; 155(7)955–961
- Haussler MR. Vitamin D receptors: nature and function. Annu Rev Nutr 1986; 6: 527–562
- DeLuca HF. The vitamin D story: a collaborative effort of basis science and clinical medicine. FASEB J 1988; 2: 224–236
- Abe E, Miyaura C, Tanaka H, Shiina Y, Kuribayashi T, Suda S, Nishii Y, DeLuca HF, Suda T. 1a,25-Dihydroxyvitamin D3 promotes fusion of mouse alveolar macrophages both by a direct mechanism and by a spleen cell-mediated indirect mechanism. Proc Natl Acad Sci USA 1983; 80: 5583–5587
- Bar-Shavit Z, Teitelbaum SL, Reitsma P, Hall A, Pegg LE, Trial J, Kahn AJ. Induction of monocytic differentiation and bone resorption by 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 1983; 80: 5907–5911
- Merke J, Klaus G, Hugel U, Waldherr R, Ritz E. No 1,25-dihydroxy D3 receptors on osteoclasts of calcium-deficient chicken despite demonstrable receptors on circulating monocytes. J Clin Invest 1986; 77: 312–314
- Pike JW. Vitamin D3 receptors: structure and function in transcription. Annu Rev Nutr 1991; 11: 189–216
- Gallagher JC, Goldgar D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med 1990; 113: 649–655
- Shiraki M, Ito H, Orimo H. The ultra long-term treatment of senile osteoporosis with 1 alpha-hydroxyvitamin D3. Bone Miner 1993; 20: 223–234
- Tilyard MW, Spears GF, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992; 326: 357–362
- Gallagher JC, Riggs BL, Recker RR, Goldgar D. The effect of clacitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency. Proc Soc Exp Biol Med 1989; 191: 287–292
- Aloia JF, Vaswani A, Yeh JK, Ellis K, Yasumura S, Cohn SH. Calcitriol in the treatment of postmenopausal osteoporosis. Am J Med 1988; 84: 401–408
- Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. Procter & Gamble Pharmaceuticals, Staines, UK. J Bone Miner Res Jun, 2000; 15(6)993–1000
- Sambrook PN, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, Eisman J. Prevention of corticosteroid osteoporosis: a comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993; 328: 1747–1752
- Canalis EM. Effect of glucocorticoids on type I collagen synthesis, alkaline phosphatase activity and deoxyribonuleic acid content in cultured fetal rat calvariae. Endocrinology 1983; 112: 931–939
- Sambrook PN. Corticosteroid induced osteoporosis. J Rheumatol 1996; 23(suppl 45)19–22
- Nielsen HK, Thomsen K, Eriksen EF, Charles P, Storm T, Mosekilde L. The effect of high dose glucocorticoid administration on serum bone gamma carboxyglutamic acid containing protein, serum alkaline phosphatase and vitamin D metabolites in normal subjects. Bone Mineral 1988; 4: 105–113
- Klein RG, Arnaud SB, Gallagher JC, Deluca HF, Riggs B. Intestinal calcium absorption in exogenous hypercorticoidism: Role of 25-hydroxyvitamin D and corticosteroid dose. J Clin Invest 1977; 60: 253–259
- Fogelman I, Blake GM. Different approaches to bone densitometry. J Nucl Med 2000; 41: 2015–2025